Brief: Pixium Vision Expects PRIMAvera Read-Out Around End-2023

Pixium Vision SA

08/12/2021 06:11

Dec 8 (Reuters) - Pixium Vision SA  ALPIX.PA :
    * GAINING CONFIDENCE IN EXECUTION TIMELINE OF PRIMAVERA
PIVOTAL
TRIAL FOLLOWING FIRST PATIENT IMPLANTATION IN UK
    * PRIMAVERA READ-OUT NOW EXPECTED AROUND END-2023
    * FOLLOWS SUCCESSFUL IMPLANTATIONS IN FRANCE AND GERMANY
    * PLANS TO EXPAND TO ADDITIONAL CLINICAL SITES IN SPAIN,
NETHERLANDS, AND ITALY THROUGHOUT H1 2022
    * PIXIUM ANTICIPATES RECRUITMENT TO COMPLETE BY END OF 2022
LEADING TO A READ-OUT OF PRIMAVERA STUDY AROUND END OF 2023
    * PRIMAVERA TRIAL WAS INITIALLY EXPECTED TO READ-OUT IN LATE
2022,
LONGER THAN EXPECTED COMPETENT AUTHORITY APPROVALS DUE TO
COVID-19 HAVE LED TO DELAYED OPENINGS OF CLINICAL CENTRES
    * A TOTAL OF 38 PATIENTS WILL BE ENROLLED IN PRIMAVERA STUDY

Source text for Eikon:  ID:nGNE1fZxtS 
Further company coverage:  ALPIX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))